12:00 AM
 | 
Oct 04, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lodenosine: Phase II

Interim data from 66 patients in UBS's 209-patient study showed a reduction in viral RNA to <50 copies/mL at 12 weeks in 55 percent of patients receiving one of three doses...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >